07:20 AM EST, 12/19/2024 (MT Newswires) -- Merck ( MRK ) said Thursday two phase 3 trials of its experimental two-drug, single-tablet regimen of doravirine and islatravir in adults with virologically suppressed HIV-1 infection met the primary efficacy and safety objectives.

The company said the experimental drug was found to be non-inferior to baseline antiretroviral therapy in one study and non-inferior to bictegravir/emtricitabine/tenofovir alafenamide in the second trial, although the superiority criteria was not met in the second trial.

Merck ( MRK ) said it plans to present the detailed findings at a future scientific conference and intends to file the data with regulatory authorities.